APP and Alzheimer disease: In the only preclinical drug study to date, Nygaard and colleagues10 assessed the responses of two common AD mouse models (APP/PS1 and 3xTg-AD) with brain amyloidosis to four AEDs, brivaracetam, ethosuximide, levetiracetam and phenytoin.